XML 99 R43.htm IDEA: XBRL DOCUMENT
v3.22.4

Revenue (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
Disaggregation of Revenue [Abstract] |
Disaggregation of Revenue [Table Text Block] | The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We allocate revenue from contracts with customers to geographic regions based on the location where the sale originated. We have revised prior periods to conform to current year presentation:
| Year Ended December 31,
| 2022 |  | 2021 |  | 2020
Businesses | U.S. |  | Int'l |  | Total |  | U.S. |  | Int'l |  | Total |  | U.S. |  | Int'l |  | Total
Endoscopy | $ | 1,341 |  |  | $ | 880 |  |  | $ | 2,221 |  |  | $ | 1,222 |  |  | $ | 919 |  |  | $ | 2,141 |  |  | 1,000 |  |  | $ | 780 |  |  | $ | 1,780 |
Urology | 1,257 |  |  | 516 |  |  | 1,773 |  |  | 1,120 |  |  | 463 |  |  | 1,583 |  |  | 918 |  |  | 368 |  |  | 1,286 |
Neuromodulation | 715 |  |  | 202 |  |  | 917 |  |  | 713 |  |  | 196 |  |  | 909 |  |  | 610 |  |  | 151 |  |  | 761 |
MedSurg | 3,312 |  |  | 1,599 |  |  | 4,911 |  |  | 3,055 |  |  | 1,578 |  |  | 4,633 |  |  | 2,528 |  |  | 1,299 |  |  | 3,827 |
Interventional Cardiology Therapies | 744 |  |  | 1,485 |  |  | 2,228 |  |  | 778 |  |  | 1,431 |  |  | 2,209 |  |  | 728 |  |  | 1,247 |  |  | 1,975 |
Watchman | 915 |  |  | 103 |  |  | 1,019 |  |  | 729 |  |  | 100 |  |  | 829 |  |  | 253 |  |  | 71 |  |  | 324 |
Cardiac Rhythm Management | 1,337 |  |  | 763 |  |  | 2,100 |  |  | 1,214 |  |  | 805 |  |  | 2,019 |  |  | 992 |  |  | 712 |  |  | 1,704 |
Electrophysiology | 275 |  |  | 310 |  |  | 585 |  |  | 128 |  |  | 237 |  |  | 365 |  |  | 118 |  |  | 169 |  |  | 287 |
Cardiology | 3,271 |  |  | 2,662 |  |  | 5,932 |  |  | 2,850 |  |  | 2,572 |  |  | 5,422 |  |  | 2,091 |  |  | 2,199 |  |  | 4,290 |
Peripheral Interventions | 1,048 |  |  | 850 |  |  | 1,899 |  |  | 996 |  |  | 824 |  |  | 1,820 |  |  | 888 |  |  | 689 |  |  | 1,577 |
Cardiovascular | 4,319 |  |  | 3,512 |  |  | 7,831 |  |  | 3,846 |  |  | 3,396 |  |  | 7,242 |  |  | 2,979 |  |  | 2,888 |  |  | 5,866 |
Other 1 | — |  |  | — |  |  | (60) |  |  | 10 |  |  | 4 |  |  | 13 |  |  | 193 |  |  | 27 |  |  | 219 |
Total Net Sales | $ | 7,632 |  |  | $ | 5,111 |  |  | $ | 12,682 |  |  | $ | 6,911 |  |  | $ | 4,978 |  |  | $ | 11,888 |  |  | $ | 5,701 |  |  | $ | 4,212 |  |  | $ | 9,913 |
(1) In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Specialty Pharmaceuticals net sales were substantially U.S. based. Refer to Note M – Segment Reporting for information on our reportable segments.
| Year Ended December 31,
Geographic Regions | 2022 |  | 2021 |  | 2020
U.S. | $ | 7,632 |  |  | $ | 6,901 |  |  | $ | 5,508 |
Europe, Middle East and Africa | 2,526 |  |  | 2,518 |  |  | 2,097 |
Asia-Pacific | 2,116 |  |  | 2,070 |  |  | 1,781 |
Latin America and Canada | 469 |  |  | 386 |  |  | 307 |
Other 1 | (60) |  |  | 13 |  |  | 219 |
Total Net Sales | $ | 12,682 |  |  | $ | 11,888 |  |  | $ | 9,913 |
Emerging Markets(2) | $ | 1,715 |  |  | $ | 1,429 |  |  | $ | 1,138 |
(2) We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, which currently include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Türkiye and Vietnam. We have revised prior period amounts to conform to the current year's presentation.

X
- References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration